 controlled trial interferon gamma infection chronic granulomatous disease International Chronic Granulomatous Disease Cooperative Study Group BACKGROUND Chronic granulomatous disease uncommon inherited disorder phagocytes defective production reactive intermediates oxygen predisposes patients pyogenic infections Evidence vitro vivo studies interferon gamma metabolic defect phagocytes efficacy interferon gamma frequency serious infections patients disease METHODS double-blind placebo-controlled study patients chronic granulomatous disease median age years Patients interferon gamma micrograms square meter body-surface area placebo times week year primary end point study time first serious infection event hospitalization parenteral antibiotics Measures phagocyte function RESULTS terms time first serious infection clear benefit interferon placebo patients serious infections patients reduction total number serious infections interferon placebo Interferon beneficial regardless age use nonuse prophylactic antibiotics mode inheritance X-linked autosomal recessive significant changes measures superoxide production phagocytes Interferon therapy evidence serious toxicity CONCLUSIONS patients chronic granulomatous disease interferon gamma therapy effective well-tolerated treatment frequency serious infections